Parabilis Medicines (NASDAQ:PBLS) Now Covered by Analysts at Evercore

Evercore began coverage on shares of Parabilis Medicines (NASDAQ:PBLS) in a report issued on Monday morning, MarketBeat reports. The brokerage issued an outperform rating on the stock.

Other analysts also recently issued research reports about the stock. Guggenheim assumed coverage on shares of Parabilis Medicines in a research note on Monday. They set a “buy” rating and a $40.00 price target for the company. Leerink Partners started coverage on Parabilis Medicines in a research report on Monday. They set an “outperform” rating and a $40.00 target price for the company. Bank of America began coverage on Parabilis Medicines in a research report on Monday. They set a “buy” rating and a $45.00 price target on the stock. Finally, Wall Street Zen upgraded Parabilis Medicines to a “hold” rating in a report on Saturday, June 20th. Four equities research analysts have rated the stock with a Buy rating, According to MarketBeat, Parabilis Medicines has an average rating of “Buy” and an average target price of $41.67.

Parabilis Medicines Stock Performance

Shares of NASDAQ:PBLS traded up $0.49 during trading hours on Monday, hitting $29.69. 42,368 shares of the company’s stock traded hands, compared to its average volume of 937,518. Parabilis Medicines has a 1 year low of $24.51 and a 1 year high of $34.47.

Insiders Place Their Bets

In related news, major shareholder Guy Levy acquired 500,000 shares of Parabilis Medicines stock in a transaction on Thursday, June 11th. The stock was acquired at an average price of $20.00 per share, for a total transaction of $10,000,000.00. Following the purchase, the insider owned 1,027,000 shares of the company’s stock, valued at approximately $20,540,000. This represents a 94.88% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Alan Sebulsky purchased 12,500 shares of Parabilis Medicines stock in a transaction that occurred on Thursday, June 11th. The shares were bought at an average price of $20.00 per share, with a total value of $250,000.00. Following the completion of the transaction, the director owned 12,500 shares of the company’s stock, valued at $250,000. This represents a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have purchased 530,000 shares of company stock valued at $10,723,528 over the last 90 days.